This document can be used to prepare or evaluate feasibility of ancillary study proposals and paper proposals, but is NOT intended for publication.
Study Case-Control Types
File Name
Data as of
Population
Data collected
One row per
Rows
spec_case_control_types_ctos_inv.dat
6/23/2025
CT+OS
Baseline, Main, Ext1, Ext2
Case/Control type
185,476
Please be careful when using these data. These assignments were created at case/control selection time and often have more to do with the complexities of the case/control selection process and the procedures required to perform the study than analysis. Study designs are often very complex and these assignments may not adequately describe those complexities. You may want to contact the study PI to determine case/control assignments appropriate for analysis.
ID - WHI Participant Common ID
Col 1
N
Missing
Min
Max
Mean
StdDev
185,476
0
100,001
299,999
199,884.209
57,656.591
STUDYID - Study ID
Col 2
Value
Description
N
%
83
Thrombotic, inflammatory and genetic markers for CHD
630
0.3
90
WHI sex hormone and genetic risk factors for hip fracture
800
0.4
97
Ovarian cancer serum markers
838
0.5
105
Carotenoids in age-related eye disease study (CAREDS)
1,989
1.1
110
Sex hormones and CHD
1,275
0.7
121
Hyperinsulinemia and ovarian cancer
445
0.2
126
Stroke risk factors and molecular markers
1,944
1
129
Diabetes+IGF-I in colorectal,breast,endometrial caner
2,599
1.4
132
Genetic and biochemical predictors of type 2 diabetes
3,782
2
133
Predictors of hypertension in white and black women
1,600
0.9
134
Estrone, HRT, and breast cancer
389
0.2
146
A prospective study of pancreatic cancer pathogenesis
416
0.2
165
Thyroid dysfunction and MI/stroke risk
4,490
2.4
167
Sex hormones and ER+/ER- breast cancer
902
0.5
179
Frailty in WHI: drugs, inflammatory and genetic markers
1,799
1
181
Hip fracture estradiol, cytokines, bone turnover
800
0.4
187
Serum fatty acids and incidence of ischemic stroke in women
1,935
1
189
Biochemical & anthropometric measures among obese
1,316
0.7
191
Biomarkers & genetic factors rel. to sarcopenia (with as199)
3,072
1.7
195
Candidate pathways in colorectal carcinogenesis
2,376
1.3
206
Selenium and colorectal cancer
1,601
0.9
207
IGF and multiple myeloma
591
0.3
208
Pro and anti-inflammatory cytokines and colorectal cancer
1,340
0.7
214
Prospective cohort in pancreatic cancer (AS146 extension)
627
0.3
238
Biochemical predictors of type 2 diabetes mellitus in women
1,941
1
242
DNA repair, telomere length and melanoma
471
0.3
254
Liu/Telomere/diabetes
4,029
2.2
266
EGFR-signaling-network activators/inhibitor & lung ca
2,982
1.6
275
Urinary levels of melatonin and risk of breast cancer
794
0.4
282
Serum markers for multi-stage ovarian cancer screening
1,750
0.9
284
Obesity/Breast Disease
2,098
1.1
290
Cadmium Exposure and Risk of Breast Cancer
1,508
0.8
292
Advanced Glycation End Products,receptor and Colorectal Ca
1,213
0.7
294
Lung CA & one-carbon metabolis
484
0.3
296
Cohort study of etiology of hepatocellular carcinoma
360
0.2
297
Estrogens, estr. metabolites & androgens/endo & ovarian ca
1,860
1
321
Estrogen DNA adducts: estrogen biomarker and breast cancer
962
0.5
325
Ethnic Differences in 25(OH)D and PTH Levels and CVD
4,812
2.6
327
Vit D/Lung Ca/never smoking
600
0.3
332
AVIIR score in predicting incident CHD
1,400
0.8
346
Serum, vitamin D, and risk of melanoma in WHI-OS
1,359
0.7
362
Glycation/obesity/pancreatic C
1,981
1.1
374
HPV /head and neck cancer
396
0.2
383
VitD/BR and Colorectal Ca
58
0
389
Multiple myeloma/adipo levels
591
0.3
402
Biomarkers and risk of ALS
362
0.2
403
Systemic and breast-cancer specific autoimmunity in the WHI
99
0.1
411
Excess mortality in women with rheumatoid arthritis
325
0.2
422
Cardiovascular biomarkers in WHI Native Americans
588
0.3
425
A Pilot Study of Urinary Bisphenol-A in WHI
90
0
455
Colorectal cancer
1,612
0.9
622
Late onset cardiotoxity and fatigue
213
0.1
659
WONDER Study
2,467
1.3
BA10
Adipokines and risk of obesity-related disease
4,519
2.4
BA11
Physical activity, obesity, inflammation and CHD
1,933
1
BA12
HRT, estrogen metabolism and breast cancer or hip fracture
2,861
1.5
BA13
B-cell stimulation markers and non-Hodgkins lymphoma
980
0.5
BA18
Followup studies of genetically determined risk factors
871
0.5
BA20
Arthritis, inflammation, thrombogenesis and CVD/mortality
13,120
7.1
BA21
Understanding the role of sex hormones in colorectal cancer
1,203
0.6
BA22
Predictive modeling for CVD in a multiethnic cohort in women
3,997
2.2
BA25
Leukocyte Telomere Dynamics
3,365
1.8
BA6
Inflamation genes, diet, medication, and cancer
4,086
2.2
BA7
Estradiol/estrogen and CHD, fx, stroke, VTE, cog imp.
3,634
2
BA8
Predictive value of nutrient biomarkers for CHD death
2,443
1.3
BA9
Biochemical antecedents of fracture in minority women
2,264
1.2
M11
NCI - Upper GI cancer GWAS and telomere length
435
0.2
W1
CT 6% Subsample, Clinic CBCs, QC Pools
4,546
2.5
W10
Biological markers of the effect of HT on breast cancer
1,510
0.8
W11
CVD biomarkers - Phase II: strokes after Feb. 2001
622
0.3
W14
CVD biomarkers - Phase I: additional assays
1,792
1
W15
Vit D and colorectal cancer or fractures in CaD trial
3,631
2
W18
HT Hormone Pretest
240
0.1
W2
OS-measurement precision study (OS-MPS)
1,082
0.6
W22
Vitamin D levels in 6% blood subsample of CaD
599
0.3
W24
Vitamin D and breast cancer in CaD trial
2,161
1.2
W27
NPAAS lab work
445
0.2
W39
27-hydroxycholesterol in CVD biomarkers (W-6)
1,163
0.6
W45
Proteomic Colon Cancer Study
200
0.1
W5
Endogenous sex hormones in DM trial
300
0.2
W54
CVD Biomarkers for 2010-2015 (SHARe cohort only)
11,967
6.5
W57
HT Proteomics on B2M and IGFBP4
706
0.4
W58
CVD, diabetes, and renal biomarkers in the EA HT Cohort
10,161
5.5
W6
HT CVD Biomarkers: study of CHD, Stroke and VTE - Phase I
Please be careful when using these data. These assignments were created at case/control selection time and often have more to do with the complexities of the case/control selection process and the procedures required to perform the study than analysis. Study designs are often very complex and these assignments may not adequately describe those complexities. You may want to contact the study PI to determine case/control assignments appropriate for analysis.